Видео с ютуба Samuel Oschin Comprehensive Cancer Institute
Dr Gong on the Benefits and Limitations of PARP Inhibitor–Based Regimens in mCRPC
Robert Figlin, MD, on choosing the most appropriate treatment algorithm for metastatic RCC patients
Robert Figlin, MD, discusses sequencing when treating metastatic RCC patients
Robert Figlin, MD, offers his opinion on interesting abstracts at ASCO 2017 related to RCC
Robert Figlin, MD, explains how checkpoint inhibitors are changing the way RCC is treated
Robert Figlin, MD, speculates on the changing landscape of RCC treatment
Dr. Figlin on TKI Therapy Options in Renal Cell Carcinoma
7/16/2018 - Session 1: Theodorescu
Dr. Figlin on Ongoing ADAPT Trial for mRCC
Robert A. Figlin, MD, considers combination I-O and TKIs indicated for the treatment of 1st line RCC
Roadmap to Resiliency: Medical Perspectives and Strategies for Managing Distress
Constantine Tam, MD & Robert Figlin, MD discuss progress in Waldenstrom’s Macroglobulinemia & ASCO20
Robert A. Figlin, MD, on I-O & TKIs available and indicated for the treatment of 2nd line RCC
Dr. Mita on Emergence of Checkpoint Inhibitors SCLC
Women's Cancer Research Institute - Cedars-Sinai Medical Center
Robert A. Figlin, MD, regarding the role of systemic therapy in oligometastatic RCC
Pink Party 2014
Every Step of the Cancer Journey | Joanne, Cedars-Sinai
A Man, An Idea, A Mission - David Kulber, MD| Cedars-Sinai
Options for Esophageal Cancer Patients | Cedars-Sinai